145 related articles for article (PubMed ID: 16460599)
1. Compatibility and stability of the novel anti-cancer agent C1311 in infusion devices and its in vitro biocompatibility.
den Brok MW; Nuijen B; Harms R; Buluran JN; Harvey MD; Grieshaber CK; Beijnen JH
J Oncol Pharm Pract; 2005 Mar; 11(1):13-9. PubMed ID: 16460599
[TBL] [Abstract][Full Text] [Related]
2. Pharmaceutical development of a parenteral lyophilised dosage form for the novel anticancer agent C1311.
Den Brok MW; Nuijen B; Kettenes-Van Den Bosch JJ; Van Steenbergen MJ; Buluran JN; Harvey MD; Grieshaber CK; Beijnen JH
PDA J Pharm Sci Technol; 2005; 59(5):285-97. PubMed ID: 16316064
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of an LC-UV method for the quantification and purity determination of the novel anticancer agent C1311 and its pharmaceutical dosage form.
den Brok MW; Nuijen B; Hillebrand MJ; Grieshaber CK; Harvey MD; Beijnen JH
J Pharm Biomed Anal; 2005 Sep; 39(1-2):46-53. PubMed ID: 15899571
[TBL] [Abstract][Full Text] [Related]
4. Compatibility and stability of Imexon in infusion devices and its in vitro biocompatibility.
den Brok MW; Nuijen B; Challa EE; Lutz C; Opitz HG; Beijnen JH
Anticancer Drugs; 2005 Aug; 16(7):727-32. PubMed ID: 16027520
[TBL] [Abstract][Full Text] [Related]
5. Compatibility and stability of aplidine, a novel marine-derived depsipeptide antitumor agent, in infusion devices, and its hemolytic and precipitation potential upon i.v. administration.
Nuijen B; Bouma M; Henrar RE; Manada C; Bult A; Beijnen JH
Anticancer Drugs; 1999 Nov; 10(10):879-87. PubMed ID: 10630355
[TBL] [Abstract][Full Text] [Related]
6. Compatibility and stability of the novel anticancer agent ES-285 x HCl formulated with 2-hydroxypropyl-beta-cyclodextrin in infusion devices.
Den Brok MW; Nuijen B; García JL; Miranda E; Calvo P; Manada C; Beijnen JH
Pharmazie; 2006 Jan; 61(1):21-4. PubMed ID: 16454201
[TBL] [Abstract][Full Text] [Related]
7. Pharmaceutical development, quality control, stability and compatibility of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum antineoplastic agent AP5346.
Van der Schoot SC; Nuijen B; Sood P; Thurmond KB; Stewart DR; Rice JR; Beijnen JH
Pharmazie; 2006 Oct; 61(10):835-44. PubMed ID: 17069422
[TBL] [Abstract][Full Text] [Related]
8. In vivo metabolism of the antitumor imidazoacridinone C1311 in the mouse and in vitro comparison with humans.
Calabrese CR; Loadman PM; Lim LS; Bibby MC; Double JA; Brown JE; Lamb JH
Drug Metab Dispos; 1999 Feb; 27(2):240-5. PubMed ID: 9929509
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the imidazoacridinone C1311 by high-performance liquid chromatography.
Calabrese CR; Loadman PM
J Chromatogr B Biomed Sci Appl; 1997 Mar; 690(1-2):275-81. PubMed ID: 9106053
[TBL] [Abstract][Full Text] [Related]
10. Stability of doripenem in vitro in representative infusion solutions and infusion bags.
Psathas PA; Kuzmission A; Ikeda K; Yasuo S
Clin Ther; 2008 Nov; 30(11):2075-87. PubMed ID: 19108795
[TBL] [Abstract][Full Text] [Related]
11. In vitro hemolysis and buffer capacity studies with the novel marine anticancer agent kahalalide F and its reconstitution vehicle cremophor EL/ethanol.
Nuijen B; Bouma M; Manada C; Jimeno JM; Bult A; Beijnen JH
PDA J Pharm Sci Technol; 2001; 55(4):223-9. PubMed ID: 11505554
[TBL] [Abstract][Full Text] [Related]
12. Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridinone antineoplastic agent C1311.
Burger AM; Jenkins TC; Double JA; Bibby MC
Br J Cancer; 1999 Sep; 81(2):367-75. PubMed ID: 10496367
[TBL] [Abstract][Full Text] [Related]
13. Compatibility study of 5-fluorouracil with PVC bags after repackaging into two types of infusion admixtures.
Benaji B; Faouzi MA; Dine T; Goudaliez F; Luyckx M; Brunet C; Kablan J; Gressier B; Cazin M; Cazin JC
Therapie; 1999; 54(5):659-63. PubMed ID: 10667105
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and tissue distribution of the imidazoacridinone C1311 in tumour-bearing mice.
Calabrese CR; Bibby MC; Double JA; Loadman PM
Cancer Chemother Pharmacol; 1998; 42(5):379-85. PubMed ID: 9771952
[TBL] [Abstract][Full Text] [Related]
15. Stability and compatibility of the investigational polymer-conjugated platinum anticancer agent AP 5280 in infusion systems and its hemolytic potential.
Bouma M; Nuijen B; Stewart DR; Rice JR; Jansen BA; Reedijk J; Bult A; Beijnen JH
Anticancer Drugs; 2002 Oct; 13(9):915-24. PubMed ID: 12394254
[TBL] [Abstract][Full Text] [Related]
16. Compatibility and stability of the investigational polypeptide marine anticancer agent kahalalide F in infusion devices.
Nuijen B; Bouma M; Manada C; Jimeno JM; Lazaro LL; Bult A; Beijnen JH
Invest New Drugs; 2001; 19(4):273-81. PubMed ID: 11561686
[TBL] [Abstract][Full Text] [Related]
17. Drug stability and compatibility in oncology care.
Williams DA
J Infus Chemother; 1996; 6(4):195-202. PubMed ID: 9229315
[TBL] [Abstract][Full Text] [Related]
18. Stability of anthracycline antitumor agents in four infusion fluids.
Poochikian GK; Cradock JC; Flora KP
Am J Hosp Pharm; 1981 Apr; 38(4):483-6. PubMed ID: 6945043
[TBL] [Abstract][Full Text] [Related]
19. [Stability and compatibility of acetaminophen, ketoprofen and amoxicillin in a fail-safe intravenous administration set].
Bernard L; Sautou V; Bourdeaux D; Chopineau J
Ann Fr Anesth Reanim; 2012 Jan; 31(1):47-52. PubMed ID: 22152998
[TBL] [Abstract][Full Text] [Related]
20. Stability experiments in human urine with EO9 (apaziquone): a novel anticancer agent for the intravesical treatment of bladder cancer.
Vainchtein LD; Rosing H; Mirejovsky D; Lenaz L; Schellens JH; Beijnen JH
J Pharm Biomed Anal; 2007 Jan; 43(1):285-92. PubMed ID: 16920321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
